Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  adenocarcinoma of the lung
Stage/Subtype:  adenocarcinoma of the lung
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 54 for your search:
Start Over
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TG4010.14/TIME, NCI-2013-00825, 8559, TG4010.14/TIME, 8559, NCT01383148
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 140503, NCI-2009-00447, CDR0000555324, ECOG-40503, NCT00499330
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9090-14, NCI-2013-01034, NCT01798485
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2303, NCI-2014-00520, 2012-005637-36, NCT01828112
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00007, NCI-2015-00219, 2014-002694-11, NCT02296125
A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT)
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 06-0691 / 201012832, NCI-2011-00543, 06-0691, 201012832, NCT00591838
MnSOD-Plasmid Liposomes in Preventing Esophageal Toxicity in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer Undergoing Chemoradiotherapy
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: UPCI #01-054, NCI-2011-02451, NCT00618917
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1206, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, 8811, NCT01386385
Vaccine Therapy in Treating Patients with Stage IV Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16439, NCI-2012-00431, MCC-16439, NCT01433172
Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5330C00004, NCI-2015-00687, NCT02264678
Docetaxel With or Without MLN1117 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MLN1117-1501, NCI-2015-00520, 2014-004281-25, U1111-1160-1736, NCT02393209
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB-IV Lung Cancer With a Light or Never Smoking History
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 0825, NCI-2013-01055, 09-0774, AVF4499s, UNC-LCCC-0825, NCT01344824
Pazopanib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Previously Treated With First-Line Therapy Containing Bevacizumab
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 0921, NCI-2013-00950, NCT01107652, NCT01262820
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients with Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1106/ACRIN 6697, NCI-2012-00107, CDR0000721619, RTOG-1106, NCT01507428
Erlotinib Hydrochloride with or without Bevacizumab in Treating Patients with Stage IV Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RC1126, NCI-2012-00053, 11-006881, Mod11-006881-13, NCT01532089
Start Over